A novel, killed-virus nasal vaccinia virus vaccine.

نویسندگان

  • Anna U Bielinska
  • Alexander A Chepurnov
  • Jeffrey J Landers
  • Katarzyna W Janczak
  • Tatiana S Chepurnova
  • Gary D Luker
  • James R Baker
چکیده

Live-virus vaccines for smallpox are effective but have risks that are no longer acceptable for routine use in populations at minimal risk of infection. We have developed a mucosal, killed-vaccinia virus (VV) vaccine based on antimicrobial nanoemulsion (NE) of soybean oil and detergent. Incubation of VV with 10% NE for at least 60 min causes the complete disruption and inactivation of VV. Simple mixtures of NE and VV (Western Reserve serotype) (VV/NE) applied to the nares of mice resulted in both systemic and mucosal anti-VV immunity, virus-neutralizing antibodies, and Th1-biased cellular responses. Nasal vaccination with VV/NE vaccine produced protection against lethal infection equal to vaccination by scarification, with 100% survival after challenge with 77 times the 50% lethal dose of live VV. However, animals protected with VV/NE immunization did after virus challenge have clinical symptoms more extensive than animals vaccinated by scarification. VV/NE-based vaccines are highly immunogenic and induce protective mucosal and systemic immunity without the need for an inflammatory adjuvant or infection with live virus.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.

متن کامل

A Recombinant Vaccinia Virus-based T Cell Vaccine against Influenza Virus Reduces Lung Viral Load upon Virus Challenge

Currently, there are only two approved vaccines against influenza virus, one containing killed virus and the other containing live, attenuated virus. Each year, there is a reformation of the vaccine formulation, depending on which strains are thought to become most dangerous in the upcoming season. Numerous groups and pharmaceutical companies are developing universal vaccines that would not req...

متن کامل

The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response.

Encephalitis is a rare, but serious complication from vaccination against smallpox using replication competent strains of vaccinia virus. In this report we describe mutants of vaccinia virus, containing N-terminal deletions of the vaccinia virus interferon resistance gene, E3L, that are attenuated for neuropathogenesis in a mouse model system. These recombinant viruses replicated to high titers...

متن کامل

Immunization against Vaccinia by Non-infective Mixtures of Virus and Immune Serum

1. Vaccine virus and specific immune serum mixed in such proportions as to produce no lesion when inoculated intradermally induce immunity when instilled into the nasal cavities of rabbits. 2. The mixture is also effective when inoculated subcutaneously. 3. Immunity is brought about with a minimum of systemic reaction and no local one. 4. When the mixtures are incompletely neutralized generaliz...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical and vaccine immunology : CVI

دوره 15 2  شماره 

صفحات  -

تاریخ انتشار 2008